Adaptive Biotechnologies (ADPT) Q3 2024: MRD Revenue Jumps 52% as ASP and Pharma Momentum Accelerate
Adaptive Biotechnologies delivered a pivotal quarter, with MRD revenue up sharply and average selling price (ASP) gains locked in for 2025. Strategic wins in Medicare pricing and expanded payer coverage, coupled with pharma study momentum, materially improved the margin and growth outlook. Execution on cost control and operational leverage is translating into a more credible path to profitability and sustained cash runway.
Summary
- MRD ASP Reset: New Medicare pricing and payer deals set a higher baseline for 2025 profitability.
- Pharma Study Surge: ODAC-driven demand and milestone wins are fueling sustained pharma revenue growth.
- Operational Leverage: Sequencing margin expansion and disciplined spend signal a maturing business model.
Business Overview
Adaptive Biotechnologies is a precision diagnostics and immune medicine company focused on leveraging immune receptor sequencing to inform disease monitoring and therapeutic development. The company’s core business is minimal residual disease (MRD) testing—primarily through its ClonoSeq platform, used in hematologic cancers for both clinical and pharmaceutical research customers. The second segment, immune medicine, develops T-cell and B-cell therapies and partners such as Genentech for oncology and autoimmune disease programs. MRD accounts for the majority of revenue, with the remainder from immune medicine partnerships and services.
Performance Analysis
MRD revenue surged 52% year-over-year, now comprising 81% of total revenue, as both clinical and pharma channels delivered record growth. Clinical MRD volume grew 30%, with multi-myeloma, ALL, and CLL as top contributors. Pharma MRD revenue grew 73%, boosted by $5 million in milestone payments and a robust funnel of new studies—16 new myeloma studies closed year-to-date, 11 post-ODAC. ASP in the U.S. increased 3% despite a $1.8 million reserve charge, reflecting early benefits from new CMS pricing and payer renegotiations.
Sequencing gross margin rose six points sequentially and 13 points year-over-year, reaching 56%, driven by workflow efficiencies and direct labor leverage. Operating spend declined 11% YoY, with R&D and G&A as primary sources of savings. Cash burn was reduced by 38% year-to-date, ending with $267 million in cash. Immune medicine revenue fell 32% due to lower Genentech amortization, though pharma and academic service revenue in that segment grew modestly. Adjusted EBITDA loss narrowed meaningfully, reflecting both top-line growth and cost discipline.
- Volume-Driven Growth: ClonoSeq test volume hit 19,600, up 30% YoY, with blood-based tests now 41% of mix.
- Pharma Pipeline Expansion: 10 myeloma trials now use ClonoSeq as a primary endpoint, up from seven last quarter.
- Margin Leverage: Sequencing margin improvement is structurally lowering per-sample costs and supporting the path to 70% long-term gross margin.
MRD’s outperformance and cost discipline are driving a faster-than-expected trajectory toward profitability, while pharma and payer tailwinds set up a structurally higher revenue base for 2025 and beyond.
Executive Commentary
"Results for the quarter are a clear testament of our continued strong execution on the top and bottom line. MRD revenue increased 52% year over year, driven by both clinical and pharma. This quarter, we reached two catalysts that will drive MRD revenue growth. One, Medicare set a new gap bill rate of $2,007 for our ClonoC test, which is a 17% increase from our previous rate under the episode structure. And two, we secured Medicare coverage for mantle cell lymphoma."
Chad Robbins, CEO & Co-founder
"Sequencing margin, which excludes milestones in Genentech amortization, was 56% for the quarter. This represents a significant increase of 13 percentage points versus prior year and six percentage points sequentially. This improvement is mainly attributed to lower overhead costs from efficiencies in the production lab and direct labor leverage, which combined drove lower cost per sample."
Kyle Piskill, Chief Financial Officer
Strategic Positioning
1. MRD ASP and Payer Leverage
Medicare’s new $2,007 gap bill rate and expanded coverage for mantle cell lymphoma set a new floor for MRD pricing. Adaptive is renegotiating commercial contracts at higher rates and expects 2025 ASP to average $1,300 per test, up $250 from 2023. This ASP reset is a major lever for margin expansion and revenue visibility, with further upside if payer conversions accelerate.
2. Pharma Study Acceleration and Milestone Revenue
ODAC’s recommendation has catalyzed pharma demand, with 16 new myeloma studies booked and 10 now using ClonoSeq as a primary endpoint. This shift shortens trial timelines and increases Adaptive’s milestone payment cadence, deepening the pharma revenue base and creating a flywheel between clinical and research adoption.
3. Operational Efficiency and Margin Expansion
Sequencing margin rose sharply due to workflow and labor efficiencies, with further savings expected from the NovaSeq platform launch in Q3 2025. Management targets 5-8% margin improvement in the first year post-launch, supporting the goal of a 70% MRD margin profile over time.
4. EMR Integration and Channel Enablement
Integration with Epic and Flatiron EMRs is driving higher account growth rates and test standardization, with 11 accounts live and 20 targeted by year-end. Accounts with EMR integration are growing faster than the rest of the business, and management expects 50% of volume to be EMR-driven by end of 2025, supporting scale and stickiness.
5. Immune Medicine Pipeline Rationalization
Immune medicine spend is being constrained as MRD outpaces it in growth and strategic priority. Oncology and autoimmune programs are advancing, but spend will be further rationalized in 2025, reflecting a disciplined capital allocation approach.
Key Considerations
This quarter marks a structural inflection for Adaptive’s business model, with higher MRD ASP, pharma momentum, and cost leverage converging to accelerate the path to profitability and cash self-sufficiency.
Key Considerations:
- ASP Upside Potential: Pace of commercial payer conversion and operational enhancements could push realized ASP above $1,300 in 2025.
- Pharma Backlog Visibility: $200 million pharma backlog and new regulatory pathways support multi-year revenue durability.
- Margin Expansion Trajectory: Sequencing cost reductions and NovaSeq launch are structurally improving gross margin, narrowing losses quarter-over-quarter.
- Channel Standardization: EMR integration is driving faster growth and higher ordering consistency, supporting account retention and volume scalability.
- Immune Medicine Focus: Lower relative spend and targeted pipeline bets reduce drag on group profitability while preserving optionality in high-value indications.
Risks
Adaptive faces payer risk, with potential for delays or resistance in commercial contract renegotiation and ongoing industry scrutiny on genetic test reimbursement. Pharma revenue remains lumpy, with milestone timing and study conversion subject to biopharma capital cycles and regulatory review. Immune medicine revenue is volatile and subject to partner pipeline reprioritization, as evidenced by Genentech amortization step-downs. Execution risk persists around EMR integration pace and NovaSeq rollout, both of which are critical to sustaining operational leverage.
Forward Outlook
For Q4 2024, Adaptive guided to:
- MRD revenue of $143 million to $145 million for the full year (raised lower end of prior range)
- Total operating spend of $335 million to $340 million (lowered from prior guide)
- Annual cash burn of ~$105 million, a 31% reduction from 2023
For full-year 2024, management emphasized:
- Strong year-to-date performance and regulatory milestones de-risking the guide
- Prudent posture on upper-end guidance due to pharma study timing volatility and hurricane-related uncertainties
Takeaways
Adaptive’s Q3 2024 results mark a turning point in both revenue quality and operational discipline.
- MRD ASP and pharma study wins are structurally raising revenue and margin potential, supporting a credible path to cash self-sufficiency.
- Cost discipline and sequencing margin gains are translating into narrower losses and extending the cash runway, with NovaSeq and EMR integration as future levers.
- Investors should track payer conversion cadence, pharma milestone realization, and the pace of operational leverage as key drivers of upside or risk in 2025 and beyond.
Conclusion
Adaptive Biotechnologies exits Q3 2024 with a stronger, more resilient business model—anchored by higher MRD pricing, pharma demand, and operational leverage. The company’s execution on both commercial and cost fronts positions it for sustainable growth and improved profitability, though payer and pharma volatility remain watchpoints.
Industry Read-Through
Adaptive’s pricing win and payer momentum signal a broader shift in the reimbursement landscape for high-value molecular diagnostics, with ASP expansion now a realistic lever for peers with strong health economics data. Pharma’s embrace of MRD as a primary endpoint is accelerating trial timelines and milestone payments, a trend likely to benefit other diagnostic platforms with regulatory-grade endpoints. Margin expansion via workflow automation and EMR integration is becoming table stakes, raising the bar for operational excellence across precision diagnostics. Industry participants should monitor payer dynamics, pharma study design, and automation investments as critical competitive differentiators in the next cycle.